Crispr Therapeutics AG (NASDAQ:CRSP) - Research analysts at Oppenheimer lowered their FY2024 earnings per share (EPS) estimates for Crispr Therapeutics in a note issued to investors on Wednesday, October 28th. Oppenheimer analyst J. Olson now expects that the company will post earnings per share of $0.18 for the year, down from their prior forecast of $0.22. Oppenheimer currently has a "Buy" rating and a $105.00 target price on the stock. Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Sunday, November 1st. The company reported ($1.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.18) by ($0.14). The business had revenue of $0.15 million during the quarter, compared to the consensus estimate of $2.22 million. Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The company's revenue for the quarter was down 99.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.40 earnings per share.
A number of other equities analysts also recently commented on the stock. Raymond James reissued a "sell" rating on shares of Crispr Therapeutics in a research note on Friday. BidaskClub raised shares of Crispr Therapeutics from a "hold" rating to a "buy" rating in a research note on Wednesday, September 2nd. Chardan Capital boosted their price objective on shares of Crispr Therapeutics from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, October 22nd. Roth Capital boosted their price objective on shares of Crispr Therapeutics from $105.00 to $115.00 and gave the stock a "buy" rating in a research note on Wednesday, October 21st. Finally, Citigroup reissued a "sell" rating on shares of Crispr Therapeutics in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company's stock. The stock currently has a consensus rating of "Buy" and an average price target of $99.56.
Shares of NASDAQ CRSP traded down $3.86 during trading hours on Friday, reaching $92.49. The stock had a trading volume of 53,802 shares, compared to its average volume of 1,022,949. The firm has a market cap of $6.76 billion, a price-to-earnings ratio of 209.46 and a beta of 2.31. The business's fifty day moving average price is $90.62 and its two-hundred day moving average price is $77.61. Crispr Therapeutics has a 52-week low of $32.30 and a 52-week high of $111.90.
In related news, Director Bradley J. Phd Bolzon sold 1,155 shares of Crispr Therapeutics stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $84.89, for a total transaction of $98,047.95. Following the transaction, the director now owns 7,391 shares of the company's stock, valued at $627,421.99. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Rodger Novak sold 25,000 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $92.62, for a total value of $2,315,500.00. Following the transaction, the president now directly owns 651,940 shares in the company, valued at approximately $60,382,682.80. The disclosure for this sale can be found here. Insiders sold 133,000 shares of company stock valued at $12,064,743 in the last three months. Insiders own 17.10% of the company's stock.
Several large investors have recently made changes to their positions in CRSP. Geode Capital Management LLC boosted its stake in Crispr Therapeutics by 9.5% during the 1st quarter. Geode Capital Management LLC now owns 42,950 shares of the company's stock valued at $1,821,000 after purchasing an additional 3,716 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Crispr Therapeutics by 42.7% in the 1st quarter. Invesco Ltd. now owns 190,307 shares of the company's stock worth $8,071,000 after buying an additional 56,928 shares during the last quarter. Advisor Group Holdings Inc. purchased a new position in shares of Crispr Therapeutics in the 1st quarter worth $821,000. HighTower Advisors LLC boosted its stake in shares of Crispr Therapeutics by 9.9% in the 1st quarter. HighTower Advisors LLC now owns 20,550 shares of the company's stock worth $873,000 after buying an additional 1,850 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of Crispr Therapeutics by 233.6% in the 1st quarter. Morgan Stanley now owns 851,519 shares of the company's stock worth $36,113,000 after buying an additional 596,255 shares during the last quarter. 55.29% of the stock is currently owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is a support level?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]